{"id":2355,"date":"2025-01-08T17:41:32","date_gmt":"2025-01-08T14:41:32","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2355"},"modified":"2025-03-07T15:26:36","modified_gmt":"2025-03-07T12:26:36","slug":"avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/de\/avidity-biosciences-prepares-for-three-rare-muscle-disease-programs-2025-bla-submission-and-commercialization\/","title":{"rendered":"Avidity Biosciences bereitet sich auf die BLA-Einreichung und Kommerzialisierung von drei Programmen f\u00fcr seltene Muskelerkrankungen im Jahr 2025 vor"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Avidity Biosciences, Inc., ein biopharmazeutisches Unternehmen, das sich der Entwicklung einer neuen Klasse von RNA-Behandlungen, den sogenannten Antik\u00f6rper-Oligonukleotid-Konjugaten (AOCsTM), verschrieben hat, berichtete heute \u00fcber seine Fortschritte und Pl\u00e4ne f\u00fcr ein bahnbrechendes Jahr 2025.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Zu diesen wichtigen erwarteten Meilensteinen geh\u00f6ren der Abschluss von drei potenziellen Registrierungsprogrammen, die Einreichung eines Biologics License Application (BLA) f\u00fcr Delpacibart Zotadirsen (del-zota) f\u00fcr Personen mit Mutationen der Muskeldystrophie Duchenne, bei denen Exon 44 \u00fcbersprungen werden kann (DMD44), die Vorbereitung mehrerer Produkteinf\u00fchrungen in den Bereichen DMD44, Myotone Dystrophie Typ 1 (DM1) und Fazioskapulohumerale Muskeldystrophie (FSHD) sowie die Gr\u00fcndung eines vollst\u00e4ndig integrierten, internationalen Gesch\u00e4fts zur Unterst\u00fctzung einer wachsenden AOC-Pipeline in den Bereichen Pr\u00e4zisionskardiologie und neuromuskul\u00e4re Erkrankungen.<\/p>","protected":false},"excerpt":{"rendered":"<p>A biopharmaceutical firm dedicated to developing a novel class of RNA treatments known as Antibody Oligonucleotide Conjugates (AOCsTM), Avidity Biosciences, Inc., today reported its advancements and plans for a game-changing year in 2025. These significant expected milestones include completing three potentially registrational programs, submitting a Biologics License Application (BLA) for delpacibart zotadirsen (del-zota) for individuals [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2357,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[126,128,130,129,66,77],"class_list":["post-2355","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-avidity-biosciences","tag-bla","tag-dm1","tag-dmd44","tag-duchenne-muscular-dystrophy","tag-exon-skipping"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/2355","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/comments?post=2355"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/posts\/2355\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media\/2357"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/media?parent=2355"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/categories?post=2355"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/de\/wp-json\/wp\/v2\/tags?post=2355"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}